** Shares of drugmaker Regeneron Pharmaceuticals REGN.O rise 2% to $606 premarket
** REGN says it has agreed to buy bankrupt genetic testing firm 23andMe Holding for $256 million
** The agreement excludes the purchase of 23andMe's telehealth service Lemonaid Health
** 23andMe's bankruptcy proceedings had drawn scrutiny from lawmakers who warned that genetic data of millions of customers could be sold to unscrupulous buyers
** Regeneron says it will comply with 23andMe's privacy policies and applicable laws with respect to the use of customer data and that it is ready to detail its intended use of the data to a court-appointed overseer
** As of last close, REGN down 16.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。